Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)
Condition(s):Prostate NeoplasmLast Updated:June 28, 2012Unknown status
Hide Studies Not Open or Pending
Condition(s):Prostate NeoplasmLast Updated:June 28, 2012Unknown status
Condition(s):Prostate CancerLast Updated:March 14, 2018Terminated
Condition(s):D011471; D064129; D035683; D009360; D014408Last Updated:December 5, 2019Unknown status
Condition(s):Ovarian Cancer; Endometrial CancerLast Updated:December 13, 2011Completed
Condition(s):Neoplasm, ProstateLast Updated:March 27, 2013Completed
Condition(s):Progesterone Primed Endometrial Protocol; Gonadotropin Releasing Hormone Antagonist Protocol; Assisted Reproductive TreatmentsLast Updated:March 7, 2024Completed
Condition(s):Advanced Prostate CancerLast Updated:July 5, 2019Completed
Condition(s):Hypogonadotropic HypogonadismLast Updated:January 11, 2022Unknown status
Condition(s):Prostate Cancer; Bone MetastasesLast Updated:March 7, 2022Unknown status
Condition(s):Hypogonadism; Spinal Cord InjuryLast Updated:March 11, 2008Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.